Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A

Frontier Biotech released its 2026 semi-annual report, achieving total operating revenue of 313 million yuan in the reporting period, a year-on-year surge of 434.27%, with net profit attributable to the parent company of 149 million yuan. Revenue mainly came from small nucleic acid technology licensing cooperation and sales of the core product Aikening. The company's small nucleic acid pipeline made key progress, with three dual-target candidate drugs FB7011, FB7023, and FB7033 advancing IND-enabling studies, while the single-target product FB7013 has received clinical trial approval and begun Phase I subject enrollment. The company reached a global licensing agreement with multinational pharmaceutical company GSK with a total deal value exceeding 1 billion US dollars, and the upfront payment and some milestone payments have been received. In addition, Vaconvir completed online sales coverage in 31 provincial-level administrative regions nationwide, the CDMO business signed orders for three new projects, and the loxoprofen sodium hot-melt adhesive patch FB3002 obtained a drug registration certificate in August 2026.

Qihe Frontier Biotech Pharmaceutical, a wholly-owned subsidiary of Frontier Biotech, has received the Drug Registration Certificate for Loxoprofen Sodium Patch issued by the National Medical Products Administration, approving the production of this drug.